Indoximod Combo Triggers Responses in Melanoma

Adding the investigational IDO-pathway inhibitor indoximod to checkpoint inhibitor therapy resulted in a 52% overall response rate in patients with advanced melanoma enrolled in a phase II trial. The combination strategy has potential as an alternative for patients whose tumors do not respond to standard therapy.